Volume 16 Supplement 1
Catalytically active guanylyl cyclase-B requires glycosylation and mutations that inhibit this process cause dwarfism
© Dickey et al. 2015
Published: 2 September 2015
C-type natriuretic peptide (CNP) is a paracrine factor that stimulates long bone growth, axonal path finding and inhibits meiosis in the oocyte . The biologic signaling receptor for CNP is guanylyl cyclase (GC)-B, also known at NPRB or NPR2 .
GC-B is a homo-oligomer, possibly a dimer, containing a glycosylated extracellular ligand-binding domain, a single membrane-spanning region, and intracellular kinase homology domain (KHD), dimerization domain and C-terminal GC catalytic domain. Phosphorylation of the region leading into and at the beginning of the kinase homology domain is required for CNP activation of GC-B and dephosphorylation inactivates the enzyme .
Homozygous inactivating mutations in GC-B result in Acromesomelic Dysplasia, Type Maroteaux (AMDM) dwarfism [4–6], and heterozygous inactivating mutations in GC-B cause non-pathological reductions in stature . Conversely, genetic mutations that increase GC-B activity result in skeletal overgrowth [8–10].
More than fifteen inactivating missense mutations in GC-B have been identified in humans. These mutations are randomly distributed from the N-terminus (P32) to the C-terminus (G959A) of the enzyme, consistent with two potential mechanisms. The first involves multiple processes like disruption of CNP or GTP binding to the extracellular or catalytic domains, respectively. The second more general mechanism involves conformational changes in secondary, tertiary or quaternary structure that preclude catalytic domain formation or activation.
Previous investigators reported that 11 out of 12 , 2 out of 3  or 1 out of 2  missense mutations inhibited the transport of GC-B to the cell surface due to defective cellular trafficking and retention in the ER as indicated by reduced immunofluorescence imaging. Thus, the current hypothesis is that AMDM mutations inactivate GC-B by disrupting intracellular trafficking. Here, we report that four intracellular GC-B mutants known to cause AMDM dwarfism bind CNP on the cell surface but have dramatically reduced catalytic activity.
We conclude that glycosylation of GC-B is required for active catalytic domain formation and that the majority of GC-B mutations that reduce stature inactivate the enzyme by decreasing receptor glycosylation not by inhibiting trafficking to the plasma membrane.
This work was supported by NIH grants R01GM098309 to L.R.P and T32AR050938 to A.B.E.
- Potter LR: Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther. 2011, 130 (1): 71-82. 10.1016/j.pharmthera.2010.12.005.PubMedGoogle Scholar
- Potter LR: Guanylyl cyclase structure, function and regulation. Cell Signal. 2011, 23 (12): 1921-1926. 10.1016/j.cellsig.2011.09.001.PubMedPubMed CentralGoogle Scholar
- Potter LR, Hunter T: Identification and characterization of the major phosphorylation sites of the B-type natriuretic peptide receptor. J Biol Chem. 1998, 273 (25): 15533-15539. 10.1074/jbc.273.25.15533.PubMedGoogle Scholar
- Bartels CF, Bukulmez H, Padayatti P, Rhee DK, van Ravenswaaij-Arts C, Pauli RM, et al: Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet. 2004, 75 (1): 27-34. 10.1086/422013.PubMedPubMed CentralGoogle Scholar
- Hachiya R, Ohashi Y, Kamei Y, Suganami T, Mochizuki H, Mitsui N, et al: Intact kinase homology domain of natriuretic peptide receptor-B is essential for skeletal development. J Clin Endocrinol Metab. 2007, 92 (10): 4009-4014. 10.1210/jc.2007-1101.PubMedGoogle Scholar
- Khan S, Hussain Ali R, Abbasi S, Nawaz M, Muhammad N, Ahmad W: Novel mutations in natriuretic peptide receptor-2 gene underlie acromesomelic dysplasia, type maroteaux. BMC Med Genet. 2012, 13: 44-PubMedPubMed CentralGoogle Scholar
- Olney RC, Bukulmez H, Bartels CF, Prickett TC, Espiner EA, Potter LR, Warman ML: Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J Clin Endocrinol Metab. 2006, 91 (4): 1229-1232. 10.1210/jc.2005-1949.PubMedGoogle Scholar
- Hannema SE, van Duyvenvoorde HA, Premsler T, Yang RB, Mueller TD, Gassner B, et al: An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities. J Clin Endocrinol Metab. 2013, 98 (12): E1988-E1998. 10.1210/jc.2013-2358.PubMedGoogle Scholar
- Miura K, Kim OH, Lee HR, Namba N, Michigami T, Yoo WJ, et al: Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene. Am J Med Genet A. 2014, 164A (1): 156-163.PubMedGoogle Scholar
- Miura K, Namba N, Fujiwara M, Ohata Y, Ishida H, Kitaoka T, et al: An Overgrowth Disorder Associated with Excessive Production of cGMP Due to a Gain-of-Function Mutation of the Natriuretic Peptide Receptor 2 Gene. PLoS One. 2012, 7 (8): e42180-10.1371/journal.pone.0042180.PubMedPubMed CentralGoogle Scholar
- Hume AN, Buttgereit J, Al-Awadhi AM, Al-Suwaidi SS, John A, Bader M, et al: Defective cellular trafficking of missense NPR-B mutants is the major mechanism underlying acromesomelic dysplasia-type Maroteaux. Hum Mol Genet. 2009, 18 (2): 267-277.PubMedGoogle Scholar
- Vasques GA, Amano N, Docko AJ, Funari MF, Quedas EP, Nishi MY, et al: Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature. J Clin Endocrinol Metab. 2013, 98 (10): E1636-E1644. 10.1210/jc.2013-2142.PubMedGoogle Scholar
- Amano N, Mukai T, Ito Y, Narumi S, Tanaka T, Yokoya S, et al: Identification and functional characterization of two novel NPR2 mutations in Japanese patients with short stature. J Clin Endocrinol Metab. 2014, 99 (4): E713-E718. 10.1210/jc.2013-3525.PubMedGoogle Scholar
- Potter LR: Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptor B: dephosphorylation is a mechanism of desensitization. Biochemistry. 1998, 37 (8): 2422-2429. 10.1021/bi972303k.PubMedGoogle Scholar
- Bryan PM, Smirnov D, Smolenski A, Feil S, Feil R, Hofmann F, et al: A sensitive method for determining the phosphorylation status of natriuretic peptide receptors: cGK-Ialpha does not regulate NPR-A. Biochemistry. 2006, 45 (4): 1295-1303. 10.1021/bi051253d.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.